Proteome SciencesPMSNF EV-to-EBIT is -7.68 as of Jul. 13, 2026. The stock has 6 warning signs investors should review. Among 104 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 961537.5% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Proteome Sciences's Enterprise Value for the quarter that ended in Dec. 2025 was $31.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences EV-to-EBIT Related Terms
Proteome Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Proteome Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's EV-to-EBIT falls into.
Proteome Sciences's current Enterprise Value is $27.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Proteome Sciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (PMSNF) has a EV-to-EBIT of -7.68 as of Jul. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry.
Is Proteome Sciences' EV-to-EBIT too high?
Proteome Sciences' current EV-to-EBIT is -7.68. Based on the distribution chart, Proteome Sciences ranks #999999 out of 104 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #999999 out of 104 companies for EV-to-EBIT. This places Proteome Sciences in the lower half of its industry. The industry median EV-to-EBIT is 22.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.67, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Proteome Sciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current EV-to-EBIT is -7.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (PMSNF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.04, compared to a current price of $0.02 — trading 49.4% below its estimated fair value. The current EV-to-EBIT is -7.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current EV-to-EBIT is -7.68 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 